In the last 16 months Evotec AG has done two deals using its porcine beta cell screening technology. The first was a collaboration with Harvard University to discover diabetes therapies targeting beta cell regeneration. This month, Johnson & Johnson snapped up the resulting portfolio of small molecules and biologics.

J&J's Janssen Pharmaceuticals Inc. subsidiary has exclusive rights to develop and commercialize the drug candidates for Type I and Type II diabetes. Evotec and Harvard will share the $8 million upfront payment, as well as potential milestone payments of up to $300 million per product plus royalties.